BiotechTube

Veronate

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nosocomial Infections

Conditions

Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia

Trial Timeline

May 1, 2004 → Jun 1, 2006

NCT ID
NCT00113191

About Veronate

Veronate is a pre-clinical stage product being developed by Bristol Myers Squibb for Nosocomial Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00113191. Target conditions include Nosocomial Infections, Sepsis, Staphylococcal Infections.

What happened to similar drugs?

0 of 4 similar drugs in Nosocomial Infections were approved

Approved (0) Terminated (1) Active (3)
🔄levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
❌vancomycin monotherapy + daptomycin monotherapyNovartisPhase 3
🔄linezolidPfizerPhase 3
🔄ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator)PfizerPhase 3

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00113191Pre-clinicalCompleted

Competing Products

7 competing products in Nosocomial Infections

See all competitors
ProductCompanyStageHype Score
levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
40
Ceftazidime-avibactamAbbViePhase 1
21
Ceftolozane/TazobactamMerckPhase 1
29
vancomycin monotherapy + daptomycin monotherapyNovartisPhase 3
32
linezolidPfizerPhase 3
40
C Group + E GroupPfizerPhase 2/3
34
ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator)PfizerPhase 3
40